KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Non-cash Items (2016 - 2023)

Teladoc Health (TDOC) has disclosed Non-cash Items for 11 consecutive years, with $2.7 million as the latest value for Q1 2023.

  • Quarterly Non-cash Items fell 98.31% to $2.7 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Mar 2023, down 98.31% year-over-year, with the annual reading at $2.7 million for FY2022, 98.87% down from the prior year.
  • Non-cash Items hit $2.7 million in Q1 2023 for Teladoc Health, down from $19.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $1.1 billion in Q4 2020 to a low of $2.6 million in Q3 2020.
  • Historically, Non-cash Items has averaged $205.8 million across 5 years, with a median of $41.0 million in 2019.
  • Biggest five-year swings in Non-cash Items: surged 3592.49% in 2021 and later plummeted 98.31% in 2023.
  • Year by year, Non-cash Items stood at $308.5 million in 2019, then surged by 245.16% to $1.1 billion in 2020, then plummeted by 77.22% to $242.6 million in 2021, then crashed by 91.94% to $19.5 million in 2022, then plummeted by 86.1% to $2.7 million in 2023.
  • Business Quant data shows Non-cash Items for TDOC at $2.7 million in Q1 2023, $19.5 million in Q4 2022, and $2.8 million in Q3 2022.